id	sid	tid	token	lemma	pos
cajgh-154	1	1	cajgh_template	cajgh_template	ADJ
cajgh-154	1	2	new	new	ADJ
cajgh-154	1	3	articles	article	NOUN
cajgh-154	1	4	in	in	ADP
cajgh-154	1	5	this	this	DET
cajgh-154	1	6	journal	journal	NOUN
cajgh-154	1	7	are	be	AUX
cajgh-154	1	8	licensed	license	VERB
cajgh-154	1	9	under	under	ADP
cajgh-154	1	10	a	a	DET
cajgh-154	1	11	creative	creative	ADJ
cajgh-154	1	12	commons	common	NOUN
cajgh-154	1	13	attribution	attribution	NOUN
cajgh-154	1	14	4.0	4.0	NUM
cajgh-154	1	15	united	unite	VERB
cajgh-154	1	16	states	states	PROPN
cajgh-154	1	17	license	license	NOUN
cajgh-154	1	18	.	.	PUNCT
cajgh-154	2	1	this	this	DET
cajgh-154	2	2	journal	journal	NOUN
cajgh-154	2	3	is	be	AUX
cajgh-154	2	4	published	publish	VERB
cajgh-154	2	5	by	by	ADP
cajgh-154	2	6	the	the	DET
cajgh-154	2	7	university	university	NOUN
cajgh-154	2	8	library	library	NOUN
cajgh-154	2	9	system	system	NOUN
cajgh-154	2	10	of	of	ADP
cajgh-154	2	11	the	the	DET
cajgh-154	2	12	university	university	PROPN
cajgh-154	2	13	of	of	ADP
cajgh-154	2	14	pittsburgh	pittsburgh	PROPN
cajgh-154	2	15	as	as	ADP
cajgh-154	2	16	part	part	NOUN
cajgh-154	2	17	of	of	ADP
cajgh-154	2	18	its	its	PRON
cajgh-154	2	19	d	d	NOUN
cajgh-154	2	20	-	-	PUNCT
cajgh-154	2	21	scribe	scribe	VERB
cajgh-154	2	22	digital	digital	ADJ
cajgh-154	2	23	publishing	publishing	NOUN
cajgh-154	2	24	program	program	NOUN
cajgh-154	2	25	and	and	CCONJ
cajgh-154	2	26	is	be	AUX
cajgh-154	2	27	cosponsored	cosponsor	VERB
cajgh-154	2	28	by	by	ADP
cajgh-154	2	29	the	the	DET
cajgh-154	2	30	university	university	PROPN
cajgh-154	2	31	of	of	ADP
cajgh-154	2	32	pittsburgh	pittsburgh	PROPN
cajgh-154	2	33	press	press	NOUN
cajgh-154	2	34	.	.	PUNCT
cajgh-154	3	1	cost	cost	NOUN
cajgh-154	3	2	-	-	PUNCT
cajgh-154	3	3	effectiveness	effectiveness	NOUN
cajgh-154	3	4	analysis	analysis	NOUN
cajgh-154	3	5	of	of	ADP
cajgh-154	3	6	denosumab	denosumab	NOUN
cajgh-154	3	7	in	in	ADP
cajgh-154	3	8	the	the	DET
cajgh-154	3	9	prevention	prevention	NOUN
cajgh-154	3	10	of	of	ADP
cajgh-154	3	11	skeletal	skeletal	ADJ
cajgh-154	3	12	-	-	PUNCT
cajgh-154	3	13	related	relate	VERB
cajgh-154	3	14	events	event	NOUN
cajgh-154	3	15	in	in	ADP
cajgh-154	3	16	patients	patient	NOUN
cajgh-154	3	17	with	with	ADP
cajgh-154	3	18	prostate	prostate	NOUN
cajgh-154	3	19	cancer	cancer	NOUN
cajgh-154	3	20	in	in	ADP
cajgh-154	3	21	kazakhstan	kazakhstan	PROPN
cajgh-154	3	22	carina	carina	PROPN
cajgh-154	3	23	bektur	bektur	PROPN
cajgh-154	3	24	&	&	CCONJ
cajgh-154	3	25	talgat	talgat	ADJ
cajgh-154	3	26	nurgozhin	nurgozhin	ADJ
cajgh-154	3	27	center	center	NOUN
cajgh-154	3	28	for	for	ADP
cajgh-154	3	29	life	life	NOUN
cajgh-154	3	30	sciences	science	NOUN
cajgh-154	3	31	,	,	PUNCT
cajgh-154	3	32	nazarbayev	nazarbayev	ADJ
cajgh-154	3	33	university	university	NOUN
cajgh-154	3	34	,	,	PUNCT
cajgh-154	3	35	astana	astana	PROPN
cajgh-154	3	36	,	,	PUNCT
cajgh-154	3	37	kazakhstan	kazakhstan	PROPN
cajgh-154	3	38	vol	vol	NOUN
cajgh-154	3	39	.	.	PROPN
cajgh-154	4	1	3	3	NUM
cajgh-154	4	2	,	,	PUNCT
cajgh-154	4	3	suppl	suppl	ADJ
cajgh-154	4	4	.	.	PUNCT
cajgh-154	5	1	(	(	PUNCT
cajgh-154	5	2	2014	2014	NUM
cajgh-154	5	3	)	)	PUNCT
cajgh-154	5	4	|	|	ADV
cajgh-154	5	5	issn	issn	VERB
cajgh-154	5	6	2166	2166	NUM
cajgh-154	5	7	-	-	SYM
cajgh-154	5	8	7403	7403	NUM
cajgh-154	5	9	(	(	PUNCT
cajgh-154	5	10	online	online	ADJ
cajgh-154	5	11	)	)	PUNCT
cajgh-154	5	12	doi	doi	NOUN
cajgh-154	5	13	10.5195	10.5195	NUM
cajgh-154	5	14	/	/	SYM
cajgh-154	5	15	cajgh.2014.154	cajgh.2014.154	VERB
cajgh-154	5	16	|	|	ADV
cajgh-154	5	17	http://cajgh.pitt.edu	http://cajgh.pitt.edu	NOUN
cajgh-154	5	18	http://www.library.pitt.edu/	http://www.library.pitt.edu/	PROPN
cajgh-154	5	19	http://www.pitt.edu/	http://www.pitt.edu/	NOUN
cajgh-154	5	20	http://www.library.pitt.edu/articles/digpubtype/index.html	http://www.library.pitt.edu/articles/digpubtype/index.html	PUNCT
cajgh-154	6	1	http://www.upress.pitt.edu/upressindex.aspx	http://www.upress.pitt.edu/upressindex.aspx	PRON
cajgh-154	6	2	http://creativecommons.org/licenses/by/3.0/us/	http://creativecommons.org/licenses/by/3.0/us/	NOUN
cajgh-154	6	3	bektur	bektur	NOUN
cajgh-154	6	4	this	this	DET
cajgh-154	6	5	work	work	NOUN
cajgh-154	6	6	is	be	AUX
cajgh-154	6	7	licensed	license	VERB
cajgh-154	6	8	under	under	ADP
cajgh-154	6	9	a	a	DET
cajgh-154	6	10	creative	creative	ADJ
cajgh-154	6	11	commons	common	NOUN
cajgh-154	6	12	attribution	attribution	NOUN
cajgh-154	6	13	4.0	4.0	NUM
cajgh-154	6	14	united	unite	VERB
cajgh-154	6	15	states	states	PROPN
cajgh-154	6	16	license	license	NOUN
cajgh-154	6	17	.	.	PUNCT
cajgh-154	7	1	this	this	DET
cajgh-154	7	2	journal	journal	NOUN
cajgh-154	7	3	is	be	AUX
cajgh-154	7	4	published	publish	VERB
cajgh-154	7	5	by	by	ADP
cajgh-154	7	6	the	the	DET
cajgh-154	7	7	university	university	NOUN
cajgh-154	7	8	library	library	NOUN
cajgh-154	7	9	system	system	NOUN
cajgh-154	7	10	of	of	ADP
cajgh-154	7	11	the	the	DET
cajgh-154	7	12	university	university	PROPN
cajgh-154	7	13	of	of	ADP
cajgh-154	7	14	pittsburgh	pittsburgh	PROPN
cajgh-154	7	15	as	as	ADP
cajgh-154	7	16	part	part	NOUN
cajgh-154	7	17	of	of	ADP
cajgh-154	7	18	its	its	PRON
cajgh-154	7	19	d	d	NOUN
cajgh-154	7	20	-	-	PUNCT
cajgh-154	7	21	scribe	scribe	VERB
cajgh-154	7	22	digital	digital	ADJ
cajgh-154	7	23	publishing	publishing	NOUN
cajgh-154	7	24	program	program	NOUN
cajgh-154	7	25	and	and	CCONJ
cajgh-154	7	26	is	be	AUX
cajgh-154	7	27	cosponsored	cosponsor	VERB
cajgh-154	7	28	by	by	ADP
cajgh-154	7	29	the	the	DET
cajgh-154	7	30	university	university	PROPN
cajgh-154	7	31	of	of	ADP
cajgh-154	7	32	pittsburgh	pittsburgh	PROPN
cajgh-154	7	33	press	press	NOUN
cajgh-154	7	34	.	.	PUNCT
cajgh-154	8	1	central	central	ADJ
cajgh-154	8	2	asian	asian	ADJ
cajgh-154	8	3	journal	journal	NOUN
cajgh-154	8	4	of	of	ADP
cajgh-154	8	5	global	global	ADJ
cajgh-154	8	6	health	health	NOUN
cajgh-154	8	7	volume	volume	NOUN
cajgh-154	8	8	3	3	NUM
cajgh-154	8	9	,	,	PUNCT
cajgh-154	8	10	suppl	suppl	ADJ
cajgh-154	8	11	.	.	PUNCT
cajgh-154	9	1	(	(	PUNCT
cajgh-154	9	2	2014	2014	NUM
cajgh-154	9	3	)	)	PUNCT
cajgh-154	9	4	|	|	ADV
cajgh-154	9	5	issn	issn	VERB
cajgh-154	9	6	2166	2166	NUM
cajgh-154	9	7	-	-	SYM
cajgh-154	9	8	7403	7403	NUM
cajgh-154	9	9	(	(	PUNCT
cajgh-154	9	10	online	online	ADJ
cajgh-154	9	11	)	)	PUNCT
cajgh-154	9	12	|	|	ADV
cajgh-154	9	13	doi	doi	X
cajgh-154	9	14	10.5195	10.5195	NUM
cajgh-154	9	15	/	/	SYM
cajgh-154	9	16	cajgh.2014.154	cajgh.2014.154	VERB
cajgh-154	9	17	|	|	ADV
cajgh-154	9	18	http://cajgh.pitt.edu	http://cajgh.pitt.edu	NOUN
cajgh-154	9	19	abstract	abstract	ADJ
cajgh-154	9	20	introduction	introduction	NOUN
cajgh-154	9	21	.	.	PUNCT
cajgh-154	10	1	bone	bone	NOUN
cajgh-154	10	2	mass	mass	NOUN
cajgh-154	10	3	loss	loss	NOUN
cajgh-154	10	4	(	(	PUNCT
cajgh-154	10	5	bml	bml	PROPN
cajgh-154	10	6	)	)	PUNCT
cajgh-154	10	7	is	be	AUX
cajgh-154	10	8	one	one	NUM
cajgh-154	10	9	of	of	ADP
cajgh-154	10	10	the	the	DET
cajgh-154	10	11	adverse	adverse	ADJ
cajgh-154	10	12	effects	effect	NOUN
cajgh-154	10	13	of	of	ADP
cajgh-154	10	14	oncological	oncological	ADJ
cajgh-154	10	15	chemotherapy	chemotherapy	NOUN
cajgh-154	10	16	,	,	PUNCT
cajgh-154	10	17	especially	especially	ADV
cajgh-154	10	18	in	in	ADP
cajgh-154	10	19	cases	case	NOUN
cajgh-154	10	20	of	of	ADP
cajgh-154	10	21	hormonal	hormonal	ADJ
cajgh-154	10	22	types	type	NOUN
cajgh-154	10	23	of	of	ADP
cajgh-154	10	24	cancer	cancer	NOUN
cajgh-154	10	25	,	,	PUNCT
cajgh-154	10	26	such	such	ADJ
cajgh-154	10	27	as	as	ADP
cajgh-154	10	28	a	a	DET
cajgh-154	10	29	prostate	prostate	NOUN
cajgh-154	10	30	cancer	cancer	NOUN
cajgh-154	10	31	(	(	PUNCT
cajgh-154	10	32	pc	pc	NOUN
cajgh-154	10	33	)	)	PUNCT
cajgh-154	10	34	.	.	PUNCT
cajgh-154	11	1	bml	bml	PROPN
cajgh-154	11	2	is	be	AUX
cajgh-154	11	3	strongly	strongly	ADV
cajgh-154	11	4	associated	associate	VERB
cajgh-154	11	5	with	with	ADP
cajgh-154	11	6	skeletal	skeletal	ADJ
cajgh-154	11	7	-	-	PUNCT
cajgh-154	11	8	related	relate	VERB
cajgh-154	11	9	events	event	NOUN
cajgh-154	11	10	(	(	PUNCT
cajgh-154	11	11	sres	sre	NOUN
cajgh-154	11	12	)	)	PUNCT
cajgh-154	11	13	,	,	PUNCT
cajgh-154	11	14	therefore	therefore	ADV
cajgh-154	11	15	decreasing	decrease	VERB
cajgh-154	11	16	the	the	DET
cajgh-154	11	17	quality	quality	NOUN
cajgh-154	11	18	of	of	ADP
cajgh-154	11	19	patient	patient	NOUN
cajgh-154	11	20	’s	’s	PART
cajgh-154	11	21	life	life	NOUN
cajgh-154	11	22	.	.	PUNCT
cajgh-154	12	1	denosumab	denosumab	NOUN
cajgh-154	12	2	shows	show	VERB
cajgh-154	12	3	an	an	DET
cajgh-154	12	4	advantage	advantage	NOUN
cajgh-154	12	5	over	over	ADP
cajgh-154	12	6	zoledronic	zoledronic	ADJ
cajgh-154	12	7	acid	acid	NOUN
cajgh-154	12	8	(	(	PUNCT
cajgh-154	12	9	za	za	PROPN
cajgh-154	12	10	)	)	PUNCT
cajgh-154	12	11	in	in	ADP
cajgh-154	12	12	delaying	delay	VERB
cajgh-154	12	13	the	the	DET
cajgh-154	12	14	first	first	ADJ
cajgh-154	12	15	onset	onset	NOUN
cajgh-154	12	16	of	of	ADP
cajgh-154	12	17	sres	sre	NOUN
cajgh-154	12	18	and	and	CCONJ
cajgh-154	12	19	subsequent	subsequent	ADJ
cajgh-154	12	20	sres	sre	NOUN
cajgh-154	12	21	in	in	ADP
cajgh-154	12	22	adults	adult	NOUN
cajgh-154	12	23	with	with	ADP
cajgh-154	12	24	pc	pc	NOUN
cajgh-154	12	25	in	in	ADP
cajgh-154	12	26	several	several	ADJ
cajgh-154	12	27	phase	phase	NOUN
cajgh-154	12	28	iii	iii	NUM
cajgh-154	12	29	clinical	clinical	ADJ
cajgh-154	12	30	trials	trial	NOUN
cajgh-154	12	31	.	.	PUNCT
cajgh-154	13	1	since	since	SCONJ
cajgh-154	13	2	generic	generic	PROPN
cajgh-154	13	3	za	za	PROPN
cajgh-154	13	4	recently	recently	ADV
cajgh-154	13	5	became	become	VERB
cajgh-154	13	6	available	available	ADJ
cajgh-154	13	7	,	,	PUNCT
cajgh-154	13	8	the	the	DET
cajgh-154	13	9	purpose	purpose	NOUN
cajgh-154	13	10	of	of	ADP
cajgh-154	13	11	the	the	DET
cajgh-154	13	12	present	present	ADJ
cajgh-154	13	13	study	study	NOUN
cajgh-154	13	14	was	be	AUX
cajgh-154	13	15	to	to	PART
cajgh-154	13	16	assess	assess	VERB
cajgh-154	13	17	the	the	DET
cajgh-154	13	18	cost	cost	NOUN
cajgh-154	13	19	-	-	PUNCT
cajgh-154	13	20	effectiveness	effectiveness	NOUN
cajgh-154	13	21	of	of	ADP
cajgh-154	13	22	denosumab	denosumab	NOUN
cajgh-154	13	23	vs.	vs.	ADP
cajgh-154	13	24	brand	brand	NOUN
cajgh-154	13	25	or	or	CCONJ
cajgh-154	13	26	generic	generic	PROPN
cajgh-154	13	27	za	za	PROPN
cajgh-154	13	28	in	in	ADP
cajgh-154	13	29	the	the	DET
cajgh-154	13	30	prevention	prevention	NOUN
cajgh-154	13	31	of	of	ADP
cajgh-154	13	32	sres	sre	NOUN
cajgh-154	13	33	in	in	ADP
cajgh-154	13	34	kazakhstani	kazakhstani	NOUN
cajgh-154	13	35	patients	patient	NOUN
cajgh-154	13	36	with	with	ADP
cajgh-154	13	37	pc	pc	NOUN
cajgh-154	13	38	.	.	PUNCT
cajgh-154	14	1	methods	method	NOUN
cajgh-154	14	2	.	.	PUNCT
cajgh-154	15	1	a	a	DET
cajgh-154	15	2	markov	markov	NOUN
cajgh-154	15	3	model	model	NOUN
cajgh-154	15	4	was	be	AUX
cajgh-154	15	5	constructed	construct	VERB
cajgh-154	15	6	in	in	ADP
cajgh-154	15	7	tree	tree	NOUN
cajgh-154	15	8	-	-	PUNCT
cajgh-154	15	9	age	age	NOUN
cajgh-154	15	10	pro	pro	ADJ
cajgh-154	15	11	2013	2013	NUM
cajgh-154	15	12	software	software	NOUN
cajgh-154	15	13	program	program	NOUN
cajgh-154	15	14	with	with	ADP
cajgh-154	15	15	4	4	NUM
cajgh-154	15	16	-	-	PUNCT
cajgh-154	15	17	week	week	NOUN
cajgh-154	15	18	model	model	NOUN
cajgh-154	15	19	cycles	cycle	NOUN
cajgh-154	15	20	to	to	PART
cajgh-154	15	21	analyze	analyze	VERB
cajgh-154	15	22	the	the	DET
cajgh-154	15	23	cost	cost	NOUN
cajgh-154	15	24	-	-	PUNCT
cajgh-154	15	25	effectiveness	effectiveness	NOUN
cajgh-154	15	26	of	of	ADP
cajgh-154	15	27	the	the	DET
cajgh-154	15	28	treatments	treatment	NOUN
cajgh-154	15	29	from	from	ADP
cajgh-154	15	30	the	the	DET
cajgh-154	15	31	perspective	perspective	NOUN
cajgh-154	15	32	of	of	ADP
cajgh-154	15	33	ministry	ministry	PROPN
cajgh-154	15	34	of	of	ADP
cajgh-154	15	35	health	health	PROPN
cajgh-154	15	36	(	(	PUNCT
cajgh-154	15	37	moh	moh	NOUN
cajgh-154	15	38	)	)	PUNCT
cajgh-154	15	39	over	over	ADP
cajgh-154	15	40	a	a	DET
cajgh-154	15	41	10	10	NUM
cajgh-154	15	42	-	-	PUNCT
cajgh-154	15	43	year	year	NOUN
cajgh-154	15	44	pc	pc	NOUN
cajgh-154	15	45	cohort	cohort	NOUN
cajgh-154	15	46	.	.	PUNCT
cajgh-154	16	1	direct	direct	ADJ
cajgh-154	16	2	costs	cost	NOUN
cajgh-154	16	3	(	(	PUNCT
cajgh-154	16	4	in	in	ADP
cajgh-154	16	5	kazakhstani	kazakhstani	NOUN
cajgh-154	16	6	monetary	monetary	ADJ
cajgh-154	16	7	units	unit	NOUN
cajgh-154	16	8	“	"	PUNCT
cajgh-154	16	9	tenge	tenge	PROPN
cajgh-154	16	10	”	"	PUNCT
cajgh-154	16	11	in	in	ADP
cajgh-154	16	12	2014	2014	NUM
cajgh-154	16	13	)	)	PUNCT
cajgh-154	16	14	included	include	VERB
cajgh-154	16	15	costs	cost	NOUN
cajgh-154	16	16	of	of	ADP
cajgh-154	16	17	drug	drug	NOUN
cajgh-154	16	18	,	,	PUNCT
cajgh-154	16	19	sre	sre	NOUN
cajgh-154	16	20	(	(	PUNCT
cajgh-154	16	21	pathologic	pathologic	ADJ
cajgh-154	16	22	fracture	fracture	NOUN
cajgh-154	16	23	,	,	PUNCT
cajgh-154	16	24	surgery	surgery	NOUN
cajgh-154	16	25	to	to	ADP
cajgh-154	16	26	bone	bone	NOUN
cajgh-154	16	27	,	,	PUNCT
cajgh-154	16	28	radiation	radiation	NOUN
cajgh-154	16	29	to	to	ADP
cajgh-154	16	30	bone	bone	NOUN
cajgh-154	16	31	,	,	PUNCT
cajgh-154	16	32	spinal	spinal	ADJ
cajgh-154	16	33	cord	cord	NOUN
cajgh-154	16	34	compression	compression	NOUN
cajgh-154	16	35	)	)	PUNCT
cajgh-154	16	36	,	,	PUNCT
cajgh-154	16	37	and	and	CCONJ
cajgh-154	16	38	adverse	adverse	ADJ
cajgh-154	16	39	events	event	NOUN
cajgh-154	16	40	treatment	treatment	NOUN
cajgh-154	16	41	.	.	PUNCT
cajgh-154	17	1	all	all	DET
cajgh-154	17	2	costs	cost	NOUN
cajgh-154	17	3	were	be	AUX
cajgh-154	17	4	discounted	discount	VERB
cajgh-154	17	5	for	for	ADP
cajgh-154	17	6	3	3	NUM
cajgh-154	17	7	%	%	NOUN
cajgh-154	17	8	per	per	ADP
cajgh-154	17	9	year	year	NOUN
cajgh-154	17	10	.	.	PUNCT
cajgh-154	18	1	effectiveness	effectiveness	NOUN
cajgh-154	18	2	was	be	AUX
cajgh-154	18	3	appraised	appraise	VERB
cajgh-154	18	4	based	base	VERB
cajgh-154	18	5	on	on	ADP
cajgh-154	18	6	the	the	DET
cajgh-154	18	7	number	number	NOUN
cajgh-154	18	8	of	of	ADP
cajgh-154	18	9	sres	sre	NOUN
cajgh-154	18	10	.	.	PUNCT
cajgh-154	19	1	health	health	NOUN
cajgh-154	19	2	states	state	NOUN
cajgh-154	19	3	were	be	AUX
cajgh-154	19	4	defined	define	VERB
cajgh-154	19	5	according	accord	VERB
cajgh-154	19	6	to	to	ADP
cajgh-154	19	7	sre	sre	NOUN
cajgh-154	19	8	occurrence	occurrence	NOUN
cajgh-154	19	9	,	,	PUNCT
cajgh-154	19	10	sre	sre	NOUN
cajgh-154	19	11	history	history	NOUN
cajgh-154	19	12	,	,	PUNCT
cajgh-154	19	13	and	and	CCONJ
cajgh-154	19	14	death	death	NOUN
cajgh-154	19	15	.	.	PUNCT
cajgh-154	20	1	the	the	DET
cajgh-154	20	2	model	model	NOUN
cajgh-154	20	3	assumed	assume	VERB
cajgh-154	20	4	that	that	SCONJ
cajgh-154	20	5	a	a	DET
cajgh-154	20	6	maximum	maximum	NOUN
cajgh-154	20	7	of	of	ADP
cajgh-154	20	8	1	1	NUM
cajgh-154	20	9	sre	sre	NOUN
cajgh-154	20	10	could	could	AUX
cajgh-154	20	11	occur	occur	VERB
cajgh-154	20	12	in	in	ADP
cajgh-154	20	13	each	each	DET
cajgh-154	20	14	cycle	cycle	NOUN
cajgh-154	20	15	.	.	PUNCT
cajgh-154	21	1	transition	transition	NOUN
cajgh-154	21	2	probabilities	probability	NOUN
cajgh-154	21	3	were	be	AUX
cajgh-154	21	4	derived	derive	VERB
cajgh-154	21	5	from	from	ADP
cajgh-154	21	6	the	the	DET
cajgh-154	21	7	relevant	relevant	ADJ
cajgh-154	21	8	phase	phase	NOUN
cajgh-154	21	9	iii	iii	NUM
cajgh-154	21	10	trials	trial	NOUN
cajgh-154	21	11	.	.	PUNCT
cajgh-154	22	1	results	result	NOUN
cajgh-154	22	2	were	be	AUX
cajgh-154	22	3	present	present	ADJ
cajgh-154	22	4	in	in	ADP
cajgh-154	22	5	the	the	DET
cajgh-154	22	6	incremental	incremental	ADJ
cajgh-154	22	7	total	total	ADJ
cajgh-154	22	8	cost	cost	NOUN
cajgh-154	22	9	per	per	ADP
cajgh-154	22	10	sre	sre	NOUN
cajgh-154	22	11	avoided	avoid	VERB
cajgh-154	22	12	.	.	PUNCT
cajgh-154	23	1	one	one	NUM
cajgh-154	23	2	-	-	PUNCT
cajgh-154	23	3	way	way	NOUN
cajgh-154	23	4	sensitivity	sensitivity	NOUN
cajgh-154	23	5	analyses	analysis	NOUN
cajgh-154	23	6	were	be	AUX
cajgh-154	23	7	performed	perform	VERB
cajgh-154	23	8	to	to	PART
cajgh-154	23	9	examine	examine	VERB
cajgh-154	23	10	the	the	DET
cajgh-154	23	11	robustness	robustness	NOUN
cajgh-154	23	12	of	of	ADP
cajgh-154	23	13	the	the	DET
cajgh-154	23	14	model	model	NOUN
cajgh-154	23	15	.	.	PUNCT
cajgh-154	24	1	results	result	NOUN
cajgh-154	24	2	.	.	PUNCT
cajgh-154	25	1	over	over	ADP
cajgh-154	25	2	the	the	DET
cajgh-154	25	3	10	10	NUM
cajgh-154	25	4	-	-	PUNCT
cajgh-154	25	5	year	year	NOUN
cajgh-154	25	6	period	period	NOUN
cajgh-154	25	7	,	,	PUNCT
cajgh-154	25	8	denosumab	denosumab	NOUN
cajgh-154	25	9	incurred	incur	VERB
cajgh-154	25	10	103,091	103,091	NUM
cajgh-154	25	11	tenge	tenge	NOUN
cajgh-154	25	12	higher	high	ADJ
cajgh-154	25	13	costs	cost	NOUN
cajgh-154	25	14	than	than	ADP
cajgh-154	25	15	brand	brand	PROPN
cajgh-154	25	16	za	za	PROPN
cajgh-154	25	17	,	,	PUNCT
cajgh-154	25	18	677,133	677,133	NUM
cajgh-154	25	19	tenge	tenge	NOUN
cajgh-154	25	20	higher	high	ADJ
cajgh-154	25	21	costs	cost	NOUN
cajgh-154	25	22	than	than	ADP
cajgh-154	25	23	generic	generic	PROPN
cajgh-154	25	24	za	za	PROPN
cajgh-154	25	25	,	,	PUNCT
cajgh-154	25	26	and	and	CCONJ
cajgh-154	25	27	0.58	0.58	NUM
cajgh-154	25	28	fewer	few	ADJ
cajgh-154	25	29	sres	sre	NOUN
cajgh-154	25	30	per	per	ADP
cajgh-154	25	31	patient	patient	NOUN
cajgh-154	25	32	with	with	ADP
cajgh-154	25	33	pc	pc	NOUN
cajgh-154	25	34	.	.	PUNCT
cajgh-154	26	1	the	the	DET
cajgh-154	26	2	estimated	estimate	VERB
cajgh-154	26	3	incremental	incremental	ADJ
cajgh-154	26	4	total	total	ADJ
cajgh-154	26	5	direct	direct	ADJ
cajgh-154	26	6	costs	cost	NOUN
cajgh-154	26	7	per	per	ADP
cajgh-154	26	8	sre	sre	NOUN
cajgh-154	26	9	avoided	avoid	VERB
cajgh-154	26	10	with	with	ADP
cajgh-154	26	11	the	the	DET
cajgh-154	26	12	use	use	NOUN
cajgh-154	26	13	of	of	ADP
cajgh-154	26	14	denosumab	denosumab	NOUN
cajgh-154	26	15	were	be	AUX
cajgh-154	26	16	177,743	177,743	NUM
cajgh-154	26	17	tenge	tenge	NOUN
cajgh-154	26	18	(	(	PUNCT
cajgh-154	26	19	instead	instead	ADV
cajgh-154	26	20	of	of	ADP
cajgh-154	26	21	brand	brand	NOUN
cajgh-154	26	22	za	za	PROPN
cajgh-154	26	23	)	)	PUNCT
cajgh-154	26	24	and	and	CCONJ
cajgh-154	26	25	1,167,470	1,167,470	NUM
cajgh-154	26	26	tenge	tenge	NOUN
cajgh-154	26	27	(	(	PUNCT
cajgh-154	26	28	instead	instead	ADV
cajgh-154	26	29	of	of	ADP
cajgh-154	26	30	generic	generic	PROPN
cajgh-154	26	31	za	za	PROPN
cajgh-154	26	32	)	)	PUNCT
cajgh-154	26	33	.	.	PUNCT
cajgh-154	27	1	results	result	NOUN
cajgh-154	27	2	were	be	AUX
cajgh-154	27	3	robust	robust	ADJ
cajgh-154	27	4	to	to	ADP
cajgh-154	27	5	oneway	oneway	ADJ
cajgh-154	27	6	sensitivity	sensitivity	NOUN
cajgh-154	27	7	analyses	analysis	NOUN
cajgh-154	27	8	.	.	PUNCT
cajgh-154	28	1	conclusions.with	conclusions.with	ADP
cajgh-154	28	2	the	the	DET
cajgh-154	28	3	assumption	assumption	NOUN
cajgh-154	28	4	that	that	SCONJ
cajgh-154	28	5	brand	brand	NOUN
cajgh-154	28	6	and	and	CCONJ
cajgh-154	28	7	generic	generic	PROPN
cajgh-154	28	8	zas	zas	X
cajgh-154	28	9	are	be	AUX
cajgh-154	28	10	equally	equally	ADV
cajgh-154	28	11	effective	effective	ADJ
cajgh-154	28	12	in	in	ADP
cajgh-154	28	13	the	the	DET
cajgh-154	28	14	prevention	prevention	NOUN
cajgh-154	28	15	of	of	ADP
cajgh-154	28	16	sres	sre	NOUN
cajgh-154	28	17	in	in	ADP
cajgh-154	28	18	pc	pc	NOUN
cajgh-154	28	19	patients	patient	NOUN
cajgh-154	28	20	,	,	PUNCT
cajgh-154	28	21	denosumab	denosumab	NOUN
cajgh-154	28	22	seems	seem	VERB
cajgh-154	28	23	to	to	PART
cajgh-154	28	24	be	be	AUX
cajgh-154	28	25	a	a	DET
cajgh-154	28	26	cost	cost	NOUN
cajgh-154	28	27	-	-	PUNCT
cajgh-154	28	28	effective	effective	ADJ
cajgh-154	28	29	alternative	alternative	NOUN
cajgh-154	28	30	for	for	ADP
cajgh-154	28	31	brand	brand	NOUN
cajgh-154	28	32	za	za	PROPN
cajgh-154	28	33	(	(	PUNCT
cajgh-154	28	34	insignificant	insignificant	ADJ
cajgh-154	28	35	difference	difference	NOUN
cajgh-154	28	36	in	in	ADP
cajgh-154	28	37	costs	cost	NOUN
cajgh-154	28	38	–	–	PUNCT
cajgh-154	28	39	less	less	ADJ
cajgh-154	28	40	than	than	ADP
cajgh-154	28	41	5	5	NUM
cajgh-154	28	42	%	%	NOUN
cajgh-154	28	43	)	)	PUNCT
cajgh-154	28	44	and	and	CCONJ
cajgh-154	28	45	a	a	DET
cajgh-154	28	46	costly	costly	ADJ
cajgh-154	28	47	alternative	alternative	NOUN
cajgh-154	28	48	for	for	ADP
cajgh-154	28	49	generic	generic	PROPN
cajgh-154	28	50	za	za	PROPN
cajgh-154	28	51	from	from	ADP
cajgh-154	28	52	the	the	DET
cajgh-154	28	53	perspective	perspective	NOUN
cajgh-154	28	54	of	of	ADP
cajgh-154	28	55	moh	moh	NOUN
cajgh-154	28	56	of	of	ADP
cajgh-154	28	57	kazakhstan	kazakhstan	PROPN
cajgh-154	28	58	.	.	PUNCT
cajgh-154	29	1	keywords	keyword	NOUN
cajgh-154	29	2	:	:	PUNCT
cajgh-154	29	3	prostate	prostate	NOUN
cajgh-154	29	4	cancer	cancer	NOUN
cajgh-154	29	5	,	,	PUNCT
cajgh-154	29	6	bone	bone	NOUN
cajgh-154	29	7	mass	mass	NOUN
cajgh-154	29	8	loss	loss	NOUN
cajgh-154	29	9	,	,	PUNCT
cajgh-154	29	10	denosumab	denosumab	NOUN
cajgh-154	29	11	,	,	PUNCT
cajgh-154	29	12	zoledronic	zoledronic	ADJ
cajgh-154	29	13	,	,	PUNCT
cajgh-154	29	14	cost	cost	NOUN
cajgh-154	29	15	-	-	PUNCT
cajgh-154	29	16	effectiveness	effectiveness	NOUN
cajgh-154	29	17	http://www.library.pitt.edu/	http://www.library.pitt.edu/	PROPN
cajgh-154	29	18	http://www.pitt.edu/	http://www.pitt.edu/	NOUN
cajgh-154	29	19	http://www.library.pitt.edu/articles/digpubtype/index.html	http://www.library.pitt.edu/articles/digpubtype/index.html	X
cajgh-154	29	20	http://www.upress.pitt.edu/upressindex.aspx	http://www.upress.pitt.edu/upressindex.aspx	NOUN